The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection

Vaccine

Volumn 25, Issue 31, 2007, Pages 5882-5891

  Toubaji, Antoun ^a   Hill, Sarah ^a   Terabe, Masaki ^a   Qian, Jiahua ^a   Floyd, Tamara ^a   Simpson, R Mark ^a   Berzofsky, Jay A ^a   Khleif, Samir N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; GM CSF; IL 2; Immunotherapy

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; PEPTIDE DERIVATIVE; PROTEIN E7; VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOSTIMULATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ANIMALS; CANCER VACCINES; CELL LINE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; VACCINES, SUBUNIT;

EID: 34447272278     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.040     Document Type: Article

References (33)

1. Boon T., Coulie P.G., and Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 18 6 (1997) 267-268
2. Boon T., and Old L.J. Cancer tumor antigens. Curr Opin Immunol 9 5 (1997) 681-683
3. Weber J. Peptide vaccines for cancer. Cancer Invest 20 2 (2002) 208-221
4. O'Hagan D.T., MacKichan M.L., and Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18 3 (2001) 69-85
5. Hunter C.A., and Reiner S.L. Cytokines and T cells in host defense. Curr Opin Immunol 12 4 (2000) 413-418
6. Irvine K.R., Rao J.B., Rosenberg S.A., and Restifo N.P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156 1 (1996) 238-245
7. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., and Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158 10 (1997) 4591-4601
8. Weiss W.R., Ishii K.J., Hedstrom R.C., Sedegah M., Ichino M., Barnhart K., et al. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 161 5 (1998) 2325-2332
9. Xiang Z., and Ertl H.C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2 2 (1995) 129-135
10. Ahlers J.D., Belyakov I.M., Matsui S., and Berzofsky J.A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 13 7 (2001) 897-908
11. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88 1 (1996) 202-210
12. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90 8 (1993) 3539-3543
13. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., and Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 158 8 (1997) 3947-3958
14. Weber J., Sondak V.K., Scotland R., Phillip R., Wang F., Rubio V., et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97 1 (2003) 186-200
15. Chianese-Bullock K.A., Pressley J., Garbee C., Hibbitts S., Murphy C., Yamshchikov G., et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174 5 (2005) 3080-3086
16. Caligiuri M.A., Murray C., Robertson M.J., Wang E., Cochran K., Cameron C., et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91 1 (1993) 123-132
17. Parada N.A., Center D.M., Kornfeld H., Rodriguez W.L., Cook J., Vallen M., et al. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol 160 5 (1998) 2115-2120
18. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 5 4 (1999) 285-294
19. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 12 (1994) 907-913
20. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 9 (1993) 2242-2249
21. Berzofsky J.A., Pendleton C.D., Clerici M., Ahlers J., Lucey D.R., Putney S.D., et al. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest 88 3 (1991) 876-884
22. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
23. Bayer A.L., Yu A., Adeegbe D., and Malek T.R. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201 5 (2005) 769-777
24. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., and Lafaille J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 196 6 (2002) 851-857
25. Malek T.R., and Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4 9 (2004) 665-674
26. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21 21 (2003) 4016-4026
27. Scheibenbogen C., Schmittel A., Keilholz U., Allgauer T., Hofmann U., Max R., et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23 2 (2000) 275-281
28. Kawamura H., Rosenberg S.A., and Berzofsky J.A. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med 162 1 (1985) 381-386
29. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Hibbitts S., Grosh W.W., Chianese-Bullock K.A., et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22 22 (2004) 4474-4485
30. Cantrell D.A., and Smith K.A. Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 158 6 (1983) 1895-1911
31. Depper J.M., Leonard W.J., Drogula C., Kronke M., Waldmann T.A., and Greene W.C. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci USA 82 12 (1985) 4230-4234
32. Pak A.S., Ip G., Wright M.A., and Young M.R. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 55 4 (1995) 885-890
33. Safwat A., Aggerholm N., Roitt I., Overgaard J., and Hokland M. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2. Eur J Cancer 40 9 (2004) 1412-1417